Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2016
At a glance
- Drugs Paclitaxel (Primary)
- Indications Peritoneal cancer
- Focus Adverse reactions
- 16 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
- 16 Dec 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
- 15 Jun 2016 Status changed from completed to active, no longer recruiting.